Nov 05, 2014
Get Market Intelligence of Hemophilia Market with DelveInsight The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor. Currently about 20,000 people have hemophilia in the US; about ...
Read More...
Aug 27, 2014
DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports. VISIT OUR WEBSITE Infectious Diseases and Vaccines The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a fi...
Read More...
Aug 20, 2014
Get informed about the Current Drugs in Pipeline with DelveInsight “'Ebola Viral Infections-Pipeline Insights, 2014′, Report About Virus Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%. Ebola first appeared in 197...
Read More...
Aug 19, 2014
The “ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report by DelveInsight provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides in...
Read More...
Aug 08, 2014
Over the past six months, DelveInsight has proven its value to their customers with its excellent deliverables. Now newly launched DelveInsight's Pipeline Reports is the answer to all looking for top notch drug development information. In the fast-paced, competitive field of clinical research, organizations must...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
Newsletter/Whitepaper